Related references
Note: Only part of the references are listed.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature
Min Yu et al.
LIPIDS IN HEALTH AND DISEASE (2020)
Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets: Lipid-lowering combination therapy
Lluis Masana et al.
CURRENT CARDIOLOGY REPORTS (2020)
DA VINCI study: Change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe
Jane K. Stock
ATHEROSCLEROSIS (2020)
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry
Kornelia Kotseva et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2019)
Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy
Maria Lorenzi et al.
CLINICAL RESEARCH IN CARDIOLOGY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study
Ivo Petrov et al.
ADVANCES IN THERAPY (2019)
Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice
Marcello Arca et al.
ATHEROSCLEROSIS (2018)
Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe
Jean Ferrieres et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2018)
Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service
Barak Zafrir et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries
Kornelia Kotseva et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2016)
Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries - Findings from the EUROASPIRE IV survey
Z. Reiner et al.
ATHEROSCLEROSIS (2016)
Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients
Anselm K. Gitt et al.
ATHEROSCLEROSIS (2016)
Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population
Lotte Kaasenbrood et al.
CIRCULATION (2016)
Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up
Leopoldo Perez de Isla et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score
Johannes A. N. Dorresteijn et al.
HEART (2013)
Everyone under statin?
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2012)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
B. Mihaylova et al.
LANCET (2012)
General cardiovascular risk profile for use in primary care - The Framingham Heart Study
Ralph B. D'Agostino et al.
CIRCULATION (2008)
Share Paper
